Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders

A. Braun, M. M. Mouradian, E. Mohr, G. Fabbrini, T. N. Chase

Research output: Contribution to journalArticlepeer-review


The motor and cognitive effects of a selective D-1 dopamine receptor agonist, SKF 39393, were assessed in patients with Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, and torsion dystonia, using a double-blind placebo-controlled design. Over daily doses ranging from 3.2 to 32 mg/kg and treatment intervals extending from one to seven weeks, no consistent changes could be discerned. The contribution of D-1 receptor mediated mechanisms to the pathophysiology of hyperkinetic extrapyramidal disorders remains uncertain.

Original languageEnglish
Pages (from-to)631-635
Number of pages5
JournalJournal of Neurology, Neurosurgery and Psychiatry
Issue number5
Publication statusPublished - 1989

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)
  • Neuropsychology and Physiological Psychology


Dive into the research topics of 'Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders'. Together they form a unique fingerprint.

Cite this